Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Child Care Health Dev ; 44(1): 124-130, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-28872218

RESUMO

BACKGROUND: The decision to lose weight among adolescents is complex and is guided by a number of body-related factors. This study examined the extent of agreement between actual weight, measured as body mass index, and self-perceived weight and assessed their relative importance in weight loss behaviour among Lebanese adolescents. METHODS: Data on 278 adolescents aged 13-17 years were drawn from the nationwide Nutrition and Non-Communicable Disease Risk Factor Survey (Lebanon, 2009). Binary multivariable logistic regressions were conducted to test associations with "effort to lose weight" as the outcome variable, controlling for a number of potential confounders. RESULTS: Close to 36% reported trying to lose weight. Around 21% and 13% were overweight and obese, respectively, and 40% and 10% perceived their weight as slightly high and very high, respectively. Inaccurate perceivers, those underestimating or overestimating their weight, constituted 39%, with overall percent agreement between actual and self-perceived weight being 60.8% (kappa statistic = 0.319, 95% CI [0.242, 0.396]). About a third of the overweight adolescents (30.5%) and more than half of the obese (56.8%) underestimated their weight. In the multivariable analysis, self-perceived weight was statistically significant and a stronger predictor of weight loss effort than body mass index (adjusted odds ratios = 14.42 and 6.42 for slightly high and very high perceived weight, respectively, compared to odds ratios = 1.47 and 2.31 for overweight and obese adolescents, respectively). CONCLUSION: Health professionals need to consider self-perceived weight in conjunction with actual weight in their pursuit of weight management goals and in planning prevention programmes that guide weight loss behaviours for adolescents.


Assuntos
Comportamento do Adolescente/psicologia , Imagem Corporal/psicologia , Peso Corporal , Comportamentos Relacionados com a Saúde , Sobrepeso/psicologia , Adolescente , Comportamento do Adolescente/etnologia , Índice de Massa Corporal , Feminino , Humanos , Líbano/epidemiologia , Masculino , Sobrepeso/epidemiologia , Autoimagem , Redução de Peso
2.
Rev Med Interne ; 30(9): 803-5, 2009 Sep.
Artigo em Francês | MEDLINE | ID: mdl-19674818

RESUMO

There are several possible pathophysiological links between the development of pulmonary hypertension and myelofibrosis with myeloid metaplasia. We report a woman with myelofibrosis and myeloid metaplasia who presented with dyspnea and massive, painful splenomegaly. Right heart catheterization evidenced pulmonary hypertension. Her management consisted of splenic irradiation associated to sildenafil. Dyspnea in patients with myelofibrosis and myeloid metaplasia can be secondary to pulmonary hypertension and conversely the differential diagnosis of pulmonary hypertension should include a myeloproliferative syndrome.


Assuntos
Dispneia/etiologia , Hipertensão Pulmonar/complicações , Mielofibrose Primária/complicações , Esplenopatias/complicações , Anticoagulantes/administração & dosagem , Anticoagulantes/uso terapêutico , Cateterismo Cardíaco , Diagnóstico Diferencial , Diuréticos/administração & dosagem , Diuréticos/uso terapêutico , Quimioterapia Combinada , Ecocardiografia Doppler , Eletrocardiografia , Feminino , Fibrinolíticos/administração & dosagem , Fibrinolíticos/uso terapêutico , Furosemida/administração & dosagem , Furosemida/uso terapêutico , Heparina de Baixo Peso Molecular/administração & dosagem , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/tratamento farmacológico , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/diagnóstico , Cuidados Paliativos , Inibidores de Fosfodiesterase/administração & dosagem , Inibidores de Fosfodiesterase/uso terapêutico , Piperazinas/administração & dosagem , Piperazinas/uso terapêutico , Purinas/administração & dosagem , Purinas/uso terapêutico , Citrato de Sildenafila , Esplenomegalia/etiologia , Esplenomegalia/radioterapia , Sulfonas/administração & dosagem , Sulfonas/uso terapêutico , Vasodilatadores/administração & dosagem , Vasodilatadores/uso terapêutico
3.
Rev Med Interne ; 32(11): e114-5, 2011 Nov.
Artigo em Francês | MEDLINE | ID: mdl-21145142

RESUMO

Many neurologic and psychiatric manifestations have been associated with systemic lupus erythematosus. Narcolepsy, currently hypothesized as related to an autoimmune process, has been rarely associated with systemic lupus erythematosus. We report a 36-year-old woman who presented with narcolepsy and who subsequently developed systemic lupus erythematosus. Excessive daytime sleepiness resolved after the administration of four intravenous bolus of cyclophosphamide and methylprednisolone followed by maintenance therapy with hydroxychloroquine, aspirine and prednisone. Narcolepsy should be included in the neuropsychiatric manifestations of systemic lupus erythematosus and it may have a parallel clinical course to the activity of the lupus.


Assuntos
Lúpus Eritematoso Sistêmico/complicações , Narcolepsia/complicações , Adulto , Aspirina/administração & dosagem , Ciclofosfamida/administração & dosagem , Quimioterapia Combinada , Feminino , Humanos , Hidroxicloroquina/administração & dosagem , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Quimioterapia de Manutenção , Metilprednisolona/administração & dosagem , Narcolepsia/diagnóstico , Narcolepsia/tratamento farmacológico , Prednisona/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA